Letrozole treatment may significantly improve live birth rate compared with artificial-cycle frozen embryo transfer in women with polycystic ovary syndrome.
Sixteen studies (controlled and non-controlled) were included in the analysis.
Researchers identified rare genetic variants in the DENND1A gene that may contribute to the distinctive hormonal traits of polycystic ovary syndrome.
Endocrine events that signal less exposure to estradiol, such as shorter reproductive span, younger age at menopause, and hysterectomy, increase dementia risk.
TherapeuticsMD announced the launch of Bijuva (estradiol and progesterone) capsules for use in women with a uterus for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
In pregnant women with polycystic ovary syndrome (PCOS), metformin treatment from the late first trimester until delivery might reduce the risk for late miscarriage and preterm birth but does not prevent gestational diabetes.
In vitro fertilization was shown to have a small but significant association with the development of childhood cancers.
Researchers have identified reproductive risk factors associated with an increased risk for total knee replacement in women with severe knee osteoarthritis.
In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.